ascuprubart (IM-101) / Immunabs - LARVOL DELTA

IM-101_MG_2.1: A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis (clinicaltrialsregister.eu) - P1/2 | N=83 | Not yet recruiting | Sponsor: Immunabs Inc.

New P1/2 trial • CNS Disorders • Myasthenia Gravis

Synergy-MG: A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis (clinicaltrials.gov) - P1/2 | N=96 | Recruiting | Sponsor: ImmunAbs Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Myasthenia Gravis

Synergy-MG: A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis (clinicaltrials.gov) - P1/2 | N=96 | Not yet recruiting | Sponsor: ImmunAbs Inc. | Trial completion date: Jun 2031 ➔ Jun 2028 | Trial primary completion date: Dec 2030 ➔ Dec 2027

Trial completion date • Trial primary completion date • CNS Disorders • Myasthenia Gravis

Synergy-MG: A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis (clinicaltrials.gov) - P1/2 | N=96 | Not yet recruiting | Sponsor: ImmunAbs Inc.

New P1/2 trial • CNS Disorders • Myasthenia Gravis

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis (Businesswire) - "ImmunAbs Inc...announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis...The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG."

IND • New P2 trial • Immunology • Myasthenia Gravis

Complete inhibition of the classical complement pathway with IM-101, a novel anti-C5 antibody, in a Phase I study (EAN 2024) - No abstract available

P1 data • Critical care